Sana Biotechnology Files 8-K with Financials

TL;DR

Sana Bio filed an 8-K with financials on 6/23/25 - nothing major, just routine.

AI Summary

On June 23, 2025, Sana Biotechnology, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate activity rather than a specific material event. No new material agreements, executive changes, or significant financial transactions were disclosed in this particular filing.

Why It Matters

This filing provides updated financial information and exhibits for Sana Biotechnology, Inc., which is standard for public companies and may be reviewed by investors for operational context.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report containing financial statements and exhibits, with no indication of new material events or risks.

Key Players & Entities

• Sana Biotechnology, Inc. (company) — Registrant
• June 23, 2025 (date) — Date of earliest event reported

FAQ

From the Filing

0000950170-25-088752.txt : 20250623 0000950170-25-088752.hdr.sgml : 20250623 20250623101046 ACCESSION NUMBER: 0000950170-25-088752 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20250623 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250623 DATE AS OF CHANGE: 20250623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sana Biotechnology, Inc. CENTRAL INDEX KEY: 0001770121 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39941 FILM NUMBER: 251063317 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (206) 701-7914 MAIL ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98102 8-K 1 sana-20250623.htm 8-K 8-K false 0001770121 0001770121 2025-06-23 2025-06-23     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025   SANA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter)             Delaware   001-39941   83-1381173 (State or other jurisdiction of incorporation)   (Commission File Number)     (IRS Employer Identification Number) 188 East Blaine Street , Suite 400 Seattle , Washington 98102 (Address of principal executive offices, including Zip Code)   Registrant’s telephone number, including area code: (206) 701-7914   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   SANA   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events. On June 23, 2025, Sana Biotechnology, Inc. (the “Company”) announced positive six-month clinical results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with the Company’s hypoimmune technology, into a patient with type 1 diabetes without any immunosuppression. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.   Item 9.01 Financial Statements and Exhibits. (d) Exhibits See the Exhibit Index below, which is incorporated by reference herein.   EXHIBIT INDEX Exhibit Number   Description 99.1 Press Release dated June 23, 2025 104 Cover Pag